SERINA THERAPEUTICS INC. (SER) Stock Price, Forecast & Analysis
USA - NYSEARCA:SER - US81751A1088 - Common Stock
SER Key Statistics, Chart & Performance
The current stock price of SER is 3.86 USD. In the past month the price decreased by -23.27%. In the past year, price decreased by -25.54%.
SER Latest News, Press Relases and Analysis
SER Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.45 | 408.15B | ||
| AMGN | AMGEN INC | 15.57 | 183.27B | ||
| GILD | GILEAD SCIENCES INC | 15.48 | 157.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.19 | 107.65B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.64 | 74.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 905.49 | 60.53B | ||
| INSM | INSMED INC | N/A | 42.73B | ||
| NTRA | NATERA INC | N/A | 29.87B | ||
| BIIB | BIOGEN INC | 9.97 | 24.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 21.55B | ||
| INCY | INCYTE CORP | 15.84 | 19.86B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.3 | 13.80B |
Related stock screener links
About SER
Company Profile
Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 12 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Company Info
SERINA THERAPEUTICS INC.
601 Genome Way,, Suite 2001
Huntsville ALABAMA US
Employees: 12
Phone: 12563279630
SERINA THERAPEUTICS INC. / SER FAQ
What does SER do?
Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 12 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
What is the current price of SER stock?
The current stock price of SER is 3.86 USD. The price increased by 2.66% in the last trading session.
What is the dividend status of SERINA THERAPEUTICS INC.?
SER does not pay a dividend.
How is the ChartMill rating for SERINA THERAPEUTICS INC.?
SER has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in SERINA THERAPEUTICS INC. be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SER.
Who owns SERINA THERAPEUTICS INC.?
You can find the ownership structure of SERINA THERAPEUTICS INC. (SER) on the Ownership tab.
SER Technical Analysis
SER Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SER. The financial health of SER is average, but there are quite some concerns on its profitability.
SER Financial Highlights
Over the last trailing twelve months SER reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 88.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.61% | ||
| ROE | -618.26% | ||
| Debt/Equity | 0 |
SER Forecast & Estimates
6 analysts have analysed SER and the average price target is 13.26 USD. This implies a price increase of 243.52% is expected in the next year compared to the current price of 3.86.
For the next year, analysts expect an EPS growth of -42.1% and a revenue growth 134.46% for SER